Vaccines are a national security issue, says global health official

Vaccines are a matter of national security, a leading global health figure said this week, warning that rising anti-vaccine sentiment worldwide could undermine efforts to fight future pandemics.

Richard Hatchett, who leads the Coalition for Epidemic Preparedness Innovations, or Cepi – a partnership of governments and philanthropies that was among the first to fund COVID-19 vaccines in January 2020 – said epidemics and pandemics remained a key global threat.

"This is a security problem, not just a global health problem, not just a development problem," he said.

NATURAL VIRUSES, LAB LEAKS, AND BIOLOGICAL THREATS

That message is central to Cepi's new push to raise $3.6 billion for its work from 2027 to 2031, Hatchett said. The coalition already has $1.1 billion in existing resources, so it is asking for a further $2.5 billion to help speed up the development of vaccines targeting pandemic and epidemic threats.

"We need to acknowledge the threats that Cepi is developing the capabilities to prepare for," he said, citing naturally emerging viruses, lab accidents and the risk of biological threats deliberately engineered by bad actors, potentially enabled by advances in artificial intelligence - advances that could also help speed up response efforts.

He said that message resonated with governments even as memories of the pandemic fade and the funding climate became more challenging, with rich countries - led by the U.S. - pulling back from aid.

The Trump administration has cut all funding in particular for Gavi, a group that helps buy vaccines for the world's poorest countries. President Donald Trump's Health Secretary, Robert F Kennedy Jr, has long promoted anti-vaccine views that contradict scientific evidence.

"I am concerned about the politicization of vaccine policy in the U.S.," Hatchett said, adding that broader anti-vaccine sentiment could also weaken uptake in future pandemics.

Last year, the U.S. cancelled more than $700 million in funding for Moderna's mRNA bird flu vaccine for humans. Cepi stepped in with $54.3 million to support late-stage development of the shot in December.

Hatchett, who will travel to the U.S. for talks in the coming weeks, said Washington understood the threat posed by epidemics and pandemics, and he expected it to remain a strong partner. He added that the country has continued to work with Cepi under the Trump administration, including on recent outbreaks of Marburg virus disease in Rwanda and Ethiopia.

-Jennifer Rigby/Reuters